Early viral kinetics do not predict treatment outcome with sofosbuvir+ribavirin for 12 or 24 weeks in HCV genotype 2/3 patients in the valence trial

2014 ◽  
Vol 52 (08) ◽  
Author(s):  
C Eisenbach ◽  
S Christensen ◽  
N Grüner ◽  
R Heyne ◽  
H Hinrichsen ◽  
...  
Keyword(s):  
Treatment Outcome ◽  
Viral Kinetics ◽  
Hcv Genotype ◽  
Genotype 2 ◽  
Hcv Genotype 2 ◽  
Early Viral Kinetics

Su1064 Early Viral Kinetics Do Not Predict Treatment Outcome With Sofosbuvir + Ribavirin for 12 or 24 Weeks in HCV Genotype 2/3 Patients in the Valence Trial

2014 ◽  
Vol 146 (5) ◽  
pp. S-978-S-979 ◽  
Author(s):  
Stefan Zeuzem ◽  
Robert Flisiak ◽  
Rob H. Hyland ◽  
Ari Illeperuma ◽  
Diana M. Brainard ◽  
...  
Keyword(s):  
Treatment Outcome ◽  
Viral Kinetics ◽  
Hcv Genotype ◽  
Genotype 2 ◽  
Hcv Genotype 2 ◽  
Early Viral Kinetics

THE IMPORTANCE OF ANTI-HCV SCREENING IN PATIENTS OF LARGE MULTIFIELD HOSPITALS

2020 ◽  
Author(s):  
E.N. Kudrjavtseva ◽  
◽  
M.I. Korabelnikova ◽  
T.A. Semenenko ◽  
Ya.V. Panasyuk ◽  
...  
Keyword(s):  
Men And Women ◽  
Hcv Genotype ◽  
Genotype 2 ◽  
Hcv Genotype 2 ◽  
Hcv Screening ◽  
Subtype 1B

In the studied cohort, HCV subtypes 1b and 3a prevailed — 47,7% and 38,9%, respectively HCV genotype 2 was detected in 7,2% of cases and HCV subtype 1a — in 5,8% of cases. HCV genotype was not determined in 0,4% of patients. Difference between a frequency of detection of subtypes 1b and 3a of HCV in men and women were recorded. Subtype 3a HCV was determined in men in 44,8% of cases, and in women — in 31,7% of cases (p < 0.01). HCV subtype 1b in women was determined with a higher frequency (55,0%, р < 0, 01), than in men (41,8%).

S2071 In HIV-HCV Co-Infected Patients with HCV Genotype 2 or 3 Infection a 6-Month Treatment with Peginterferon Alpha Plus Ribavirin Has the Same Efficacy As in Mono-Infected Patients

2009 ◽  
Vol 136 (5) ◽  
pp. A-324
Author(s):  
Jean-Jacques Gonvers ◽  
Markus H. Heim ◽  
Matthias Cavassini ◽  
Beat Müllhaupt ◽  
Daniel Genné ◽  
...  
Keyword(s):  
Hcv Genotype ◽  
Genotype 2 ◽  
Hcv Genotype 2

Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection

2015 ◽  
Vol 148 (2) ◽  
pp. 355-366.e1 ◽  
Author(s):  
Gregory J. Dore ◽  
Eric Lawitz ◽  
Christophe Hézode ◽  
Stephen D. Shafran ◽  
Alnoor Ramji ◽  
...  
Keyword(s):  
Duration Of Treatment ◽  
Hcv Genotype ◽  
Genotype 2 ◽  
Hcv Genotype 2 ◽  
Peginterferon And Ribavirin

O8 SUCCESSFUL RETREATMENT WITH SOFOSBUVIR-CONTAINING REGIMENS FOR HCV GENOTYPE 2 OR 3 INFECTED PATIENTS WHO FAILED PRIOR SOFOSBUVIR PLUS RIBAVIRIN THERAPY

2014 ◽  
Vol 60 (1) ◽  
pp. S4-S5 ◽  
Author(s):  
R. Esteban ◽  
L. Nyberg ◽  
J. Lalezari ◽  
L. Ni ◽  
B. Doehle ◽  
...  
Keyword(s):  
Hcv Genotype ◽  
Genotype 2 ◽  
Hcv Genotype 2

37 SUSTAINED VIROLOGIC RESPONSE (SVR) FOLLOWING RG7128 1500MG BID/PEG-IFN/RBV FOR 28 DAYS IN HCV GENOTYPE 2/3 PRIOR NON-RESPONDERS

2010 ◽  
Vol 52 ◽  
pp. S16 ◽  
Author(s):  
E.J. Gane ◽  
M. Rodriguez-Torres ◽  
D.E. Nelson ◽  
I.M. Jacobson ◽  
J.G. McHutchison ◽  
...  
Keyword(s):  
Sustained Virologic Response ◽  
Virologic Response ◽  
Hcv Genotype ◽  
Genotype 2 ◽  
Hcv Genotype 2

Sofosbuvir-based regimens against an “easy” villain: HCV genotype 2

2017 ◽  
Vol 37 (8) ◽  
pp. 1252-1253 ◽  
Author(s):  
Giuseppe Bruno ◽  
Annalisa Saracino ◽  
Michele Milella ◽  
Gioacchino Angarano
Keyword(s):  
Hcv Genotype ◽  
Genotype 2 ◽  
Hcv Genotype 2
Sign in / Sign up

Export Citation Format

Share Document